Work

Neoadjuvant toripalimab plus CapeOX in patients with locally advanced EBV-positive gastric or esophagogastric junction adenocarcinoma (GC/EGJC): Results from the phase II NICE trial.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.4069

Authors: Liying Zhao, Li Guoxin, Hao Liu, Yanfeng Hu, Jiang Yu, Shu-Qiang Yuan, Xinhua Chen, Li Liang, Lina Yu, Fengping Li, Huayuan Liang, Huimin Zhang, Tian Lin, Mingli Zhao, Yaoxu Chen, Tao Chen, Hao Chen, Fangqin Xue, Xuefeng Zhong

Institutions: Nanfang Hospital, Southern Medical University, Beijing Tsinghua Chang Gung Hospital, Tsinghua University, Sun Yat-sen University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, 3D Medicines, Inc. (China), Fujian Provincial Hospital

Language: English

Topic: Gastric Cancer Management and Outcomes

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410816686

Cites:

Cited by:

Related to: 10